Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE Phase II lenvatinib monotherapy in anaplastic thyroid cancer
jRCTs031180236Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in anaplastic thyroid cancer (ATC), sponsored by Eisai Co., Ltd. Primary endpoint: Overall Survival. Started Apr 2016; status: completed.
02
Drugs
lenvatinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on jRCTs031180236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180236.